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Background: Lateral flow device (LFD) viral antigen immunoassays have been developed around the world as
diagnostic tests for SARS-CoV-2 infection. They have been proposed to deliver an infrastructure-light, cost-
economical solution giving results within half an hour.
Methods: LFDs were initially reviewed by a Department of Health and Social Care team, part of the UK gov-
ernment, from which 64 were selected for further evaluation from 1st August to 15th December 2020. Stand-
ardised laboratory evaluations, and for those that met the published criteria, field testing in the Falcon-C19
research study and UK pilots were performed (UK COVID-19 testing centres, hospital, schools, armed forces).
Findings: 4/64 LFDs so far have desirable performance characteristics (orient Gene, Deepblue, Abbott and
Innova SARS-CoV-2 Antigen Rapid Qualitative Test). All these LFDs have a viral antigen detection of >90% at
100,000 RNA copies/ml. 8951 Innova LFD tests were performed with a kit failure rate of 5.6% (502/8951, 95%
CI: 5.16.1), false positive rate of 0.32% (22/6954, 95% CI: 0.200.48). Viral antigen detection/sensitivity
across the sampling cohort when performed by laboratory scientists was 78.8% (156/198, 95% CI 72.484.3).
Interpretation: Our results suggest LFDs have promising performance characteristics for mass population test-
ing and can be used to identify infectious positive individuals. The Innova LFD shows good viral antigen
detection/sensitivity with excellent specificity, although kit failure rates and the impact of training are poten-
tial issues. These results support the expanded evaluation of LFDs, and assessment of greater access to testing
on COVID-19 transmission.
Funding: Department of Health and Social Care. University of Oxford. Public Health England Porton Down,
Manchester University NHS Foundation Trust, National Institute of Health Research.
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National governments and international organisations includ-
ing the World Health Organisation (WHO) and European Commis-
sion have highlighted the importance of individual testing, mass
population testing and subsequent contact tracing to halt the
chain of transmission of SARS-CoV-2, the virus responsible for
COVID-19 [1,2,3]. The current diagnostic test involves reverse-
transcription polymerase chain reaction (RT-PCR) testing of nose/
throat swabs in specialised laboratories. Such capacity in the UK
is currently estimated at ~500,000 tests/day [47]. and this is
used with contact tracing procedures and mobile applications to
identify close symptomatic contacts of infected symptomatic indi-
viduals [810]. However, there are significant challenges in creat-
ing testing capacity to identify those with asymptomaticinfections or to test contacts of individuals with COVID-19. To
date, turnaround time for issuing results from RT-PCR has been
typically slow (>24 h), though, the time of test of RT-PCR is usu-
ally a few hours.
To better understand and control SARS-CoV-2 transmission, there
is an urgent need for large-scale, accurate, affordable and rapid diag-
nostic testing assays, with the ability to detect infectious individuals.
Lateral flow device (LFD) immunoassays can be designed to test for
different protein targets and are routinely used in healthcare settings
principally as a result of their affordability, ease of use, short turn-
around time, and high-test accuracy. In brief, a sample is placed on a
conjugation pad where the analyte (or antigen) of interest is bound
by conjugated antibodies. The analyte-antibody mix subsequently
migrates along a membrane by capillary flow across both ‘test’ and
‘control’ strips. These strips are coated with antibodies detecting the
analyte of interest and a positive test is confirmed by the appearance
of coloured control and test lines [11].
Research in context
Evidence before this study
Lateral flow devices are a new form of testing for SARS-CoV-2.
They differ from RT-PCR tests in that they rely on the detection
of viral antigens by immunoassays and their utility has not yet
been fully defined. A literature review was performed in
PubMed and bioRxiv/medRxiv for all studies using lateral flow
devices for the detection of SARS-CoV-2 viral antigen. This used
the search terms “COVID-19”, “SARS-CoV-2”, “viral antigen”
and “lateral flow devices” and was not limited to English lan-
guage publications. To date, the majority of studies have been
largely single centre studies analysing a single test and there
are contrasting results with some LFDs showing good sensitiv-
ity and specificity, and others demonstrating poorer
performance.
Added value of this study
This UK COVID-19 Lateral Flow Oversight group study is the
largest national evaluation undertaken of viral antigen LFDs for
COVID-19. We have flagged four LFDs with the best perfor-
mance characteristics from our assessments. The Innova LFD
has been tested the most extensively and has high specificity
with acceptable sensitivity. Our data has also highlighted the
critical importance of training. We also note the need for fur-
ther clinical studies to demonstrate that the identification of
individuals with higher viral loads will be of benefit in inter-
rupting transmission.
Implications of all the available evidence
Our data indicates that LFDs for COVID-19 have performance
characteristics attractive for the UK mass testing program.
Ongoing iterative evaluation of the population-level roll-out of
LFDs in reducing transmission of COVID-19, and the contribu-
tion of such tests to reducing the risk of morbidity and mortal-
ity for clinically vulnerable individuals, is desirable. Further
work is required to determine the amount and content of
“training” to derive optimal test performance.
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of specific viral proteins, using conjugated antibodies to bind spike,
envelope, membrane or nucleocapsid proteins. In contrast to the
IgM/IgG “antibody tests”, these antigen tests directly identify viral
proteins, and are not reliant on the host’s immune response. In con-
trast to RT-PCR, results for LFDs are observed in 1030 min depend-
ing on the device, providing a window for early interventions to halt
the chain of transmission earlier in the disease course when individu-
als are most infectious [12].
To date, many manufacturers have developed first-generation
rapid SARS-CoV-2 antigen-detecting LFDs. However, many of these
tests have not been independently validated. There is evidence of
variable performance when assessing test sensitivity and specificity,
although several candidates looked promising on the basis of early
data [1315]. An independent national evaluation of these devices is
important to facilitate population-level or mass testing initiatives
globally.
Here, we report the diagnostic performance of first-generation
SARS-CoV-2 antigen-detecting LFD for rapid point-of-care (POC) test-
ing in work that was commissioned by the UK’s Department of Health
and Social Care (DHSC) from PHE Porton Down and the University of
Oxford.2. Methods
A phased evaluation of available SARS-CoV-2 antigen LFDs was
undertaken from 15th August to December 2020. The number of tests
required at each phase of evaluations were defined a priori and pub-
lished online [16].
2.1. Department of health and social care evaluation (Phase 1
evaluation)
The DHSC identified manufacturers supplying SARS-CoV-2 anti-
gen LFDs that could enable mass testing at a population level. A desk-
top review was performed to ensure there were appropriate
instructions for use and to assess manufacturers’ claimed perfor-
mance and manufacturing capabilities. Manufacturers were not
assessed if they had limited evidence of efficacy, a low manufacturing
capacity, in very early stages of development or unwilling to supply
kits for testing in the UK development pipeline.2.2. Pre-clinical evaluation (Phase 2 evaluation)
Pre-clinical evaluation of candidate LFDs was performed by
trained laboratory scientists at Public Health England (PHE) Porton
Down. LFDs were evaluated against SARS-CoV-2 spiked positive con-
trols and known negative controls, consisting of saliva collected from
healthy adult staff volunteers. Approval for this project was obtained
by PHE Porton down, and as no patient samples were utilised, con-
sent was not required. Viral inactivation was performed using AVL
buffer (Qiagen) and 5% Triton-X100.
Results were recorded as positive, negative or void with no possi-
bility of recording indeterminate results. Pre-defined and publicly
available “prioritisation” criteria to pass on to the next evaluation
phase had to be met for LFDs, consisting of (i) a kit failure rate of
<10%; (ii) an analytical specificity of 97%, and (iii) an analytical LOD
of 9 of 15 (60%) at 102 pfu/mL (plaque forming units per millilitre),
corresponding to a RT-PCR cycle threshold (Ct) of approximately 25
(~100,000 RNA copies/ml); and (iv) lack of cross-reactivity with sea-
sonal coronaviruses to further test analytical specificity [16].2.3. Retrospective secondary care evaluation (Phase 3a evaluation)
Evaluation using patient samples retrospectively was started in
August 2020 at PHE Porton Down. Institutional ethical assessment
and approval for this project was obtained from the University of
Oxford. Surplus samples were used anonymously as an audit of
COVID-19 tests and enabled evaluation without express consent
from individuals. Samples were obtained from a secondary health-
care setting (Oxford University Hospitals NHS Foundation Trust).
Samples were analysed against RT-PCR to determine false positives
and negatives (see supplementary methods).
 1000 SARS-CoV-2 negative samples: fresh swabs samples in VTM
held at 4oC were supplied the day after they were tested negative
by RT-PCR by the laboratory service at the John Radcliffe Hospital,
Oxford, UK.
 200 SARS-CoV-2 positive samples: swabs collected in VTM from
patients admitted to hospital during the first wave of the UK pan-
demic (March-June 2020) [17]. These swabs generally consisted of
MWE microbiology transport swabs. These were diluted 1:4
SARS-CoV-2 RT-PCR negative saliva, aliquoted and frozen at 20 °
C for later use. For each positive sample, in addition to the original
diagnostic RT-PCR Ct value, a confirmatory RT-PCR was performed
at PHE Porton Down on the diluted sample to determine the new
Ct value.
Table 1
Limit of detection for SARS-CoV-2 detection by the Innova LFD for antigen
detection using saliva sample spiked with SARS-CoV-2. Ct - cycle threshold. PFU
- plaque forming units.
PFU/ml Ct equivalent Positive LFD tests/total LFD tests % positive
100,000 16 20/20 100
10,000 19 25/25 100
1000 23.7 65/65 100
390 25.2 5/5 100
100 25.5 63/65 96
40 28.5 3/5 60
20 29.3 0/5 0
10 30.2 0/5 0
5 31 0/5 0
2.5 31.7 0/5 0
1.2 32.5 0/5 0
T. Peto et al. / EClinicalMedicine 36 (2021) 100924 32.4. Community research evaluation (Phase 3b evaluation)
We undertook a field evaluation using samples from volunteers in
the community in collaboration with the National Institute for Health
Research (NIHR) funded CONDOR Platform “COVID-19 National Diag-
nostic Research and Evaluation Platform”. This was performed under
ethical approval obtained from the FALCONC19 study (Facilitating
Accelerated Clinical Validation Of Novel diagnostics for COVID-19,
20/WA/0169, IRAS 284,229. All individuals gave expressed consent
for use of their data.). The study was conducted between 17th Sep-
tember and 23rd October 2020. This involved the recruitment and
re-testing of a consecutive series of consenting adults with a RT-PCR-
confirmed diagnosis of SARS-CoV-2 infection within 5 days of the
original PCR result. LFD testing was performed at PHE Porton Down
with the operators being unaware of clinical information from the
study participants.
For the Innova SARS-CoV-2 Antigen Rapid Qualitative Test, testing
was additionally performed for a subset of samples on-site at four
COVID-19 testing centres by trained research staff using the “dry
swabs” to evaluate “real-life”/diagnostic performance. Dry swabs are
swabs included in the kit provided by the manufacturer that are not
placed into viral transport medium prior to performing the LFD test.
2.5. Community field service evaluation (Phase 4 evaluation)
Wider field service evaluations were performed within a number
of UK institutions and settings. These evaluations utilised the Innova
SARS-CoV-2 Antigen Rapid Qualitative Test. These institutions
included a secondary healthcare setting (John Radcliffe Hospital,
Oxford), PHE Porton Down, armed forces members (following an out-
break) and in secondary schools (pupils aged 1118). Evaluations
were also undertaken at regional COVID-19 testing centres as part of
an NHS Test and Trace service evaluation involving the general pub-
lic. The John Radcliffe Hospital, Oxford performed an evaluation as
part of their asymptomatic staff screening service using the Respira-
tory Diagnostic Kit Evaluation (‘Red Kite’) study (Research Ethics
Committee reference: 19/NW/0730; North West-Greater Manchester
South Research Ethics Committee).
2.6. Statistical analyses
Fisher’s exact were used to determine non-random associations
between categorical variables. Statistical analyses and data visualisa-
tion were performed using R version 4.0.3. Sensitivity and specificity
and 95% confidence intervals were calculated using the exact Clop-
per-Pearson method. Missing data was excluded. P-value less than or
equal to 0.05 is considered statistically significant.
2.7. Role of the funding source
This work was supported by the UK Government’s Department of
Health and Social Care. This work was supported by the National
Institute for Health Research Health Protection Research Unit (NIHR
HPRU) in Healthcare Associated Infections and Antimicrobial Resis-
tance at Oxford University in partnership with Public Health England
(PHE) (NIHR200915), the NIHR Biomedical Research Centre, Oxford
and the University of Manchester The views expressed in this publi-
cation are those of the authors and not necessarily those of the NHS,
the National Institute for Health Research, the Department of Health
or Public Health England. These funders had a role in the design of
this study and did have a role during its execution, analyses, interpre-
tation of the data, and decision to submit the results. L. Y. W. L. is
supported by the NIHR Oxford BRC. A. S. W. is an NIHR Senior Investi-
gator. D. W. E. is a Robertson Foundation Fellow and an NIHR Oxford
BRC Senior Fellow.3. Results
3.1. Phase 1
A total of 132 suppliers of SARS-CoV-2 antigen detection LFDs
were identified and referred to the DHSC for initial Phase 1 review.
among these, at the time of publication, 64 were selected by the
DHSC for further evaluation by the UK lateral flow oversight group.
3.2. Phase 2
As part of Phase 2 evaluations, 9692 LFD tests were performed at
PHE Porton Down across the 64 candidate devices as of the 3rd
December 2020. 5 LFDs had a kit failure rate above the pre-specified
threshold for exclusion (>10%), 17 kits had a false-positive rate below
the pre-defined specificity threshold (<97%) and 28 kits a false-nega-
tive rate below the LOD threshold (<60% at 102 pfu/m). In total,
across all three criteria, nineteen kits performed at a level in accor-
dance with the UK Lateral Flow Oversight Group’s a priori “prioritisa-
tion criteria”. All nineteen kits also passed cross-reactivity analyses
against seasonal human coronaviruses.
The limit of detection of plaque forming units was studied more
extensively with Innova (see Table1). This analysis consisted of saliva
spiked with SARS-CoV-2 with stock of SARS-CoV-2 with a standar-
dised PFU. Under these ideal concentrations, at an estimated PFU
of 390/mL, which corresponds to a Ct of ~25, the LFD identified all
samples.
3.3. False positive rates of LFDs
The False positive rate varied from <0.1% to 0.3% on all the LDS
using PCR negative saliva samples (see Supplementary Table 1). More
extensive testing was performed on the Innova LFD, for which we
had a sufficient supply of kits available for wider testing at the time.
Device specificity was determined through an analysis of 6954. The
percentage of false-positives ranged from 0.00 to 0.49%, with an over-
all specificity of 99.68%. The false-positive rate was centre-dependent
(p = 0.014, Fisher’s exact test). These evaluations noted that where
there were challenges in interpreting the results when the test result
was “weak” (i.e. the test line was very faint) (Table 2).
3.4. Kit failure rate of innova
Across Phase 24 evaluation stages, 8951 Innova LFD tests were
performed, including a diverse cohort of populations as part of Phase
3b and Phase 4 testing, namely out-patient SARS-CoV-2 cases, health-
care staff, armed forces personnel and secondary school children. The
overall kit failure rate for the Innova LFD was 5.6% (502/8951, 95% CI:
5.16.1) (Table 3). The most common reason for kit failure was poor
Table 2
Number of false positives in negative samples in each evaluation stage for the
Innova LFD. 95% confidence intervals presented in each case.
Evaluation Phase False positives/total
number
False positive rate (95%
confidence interval)























TOTAL 22/6954 0.3% (0.20.5)
*This was 1 weak positive result that was also a weak positive on repeating; ** Weak
positive results were negative on retesting with Innova; *** Not photographed or
repeated. Taken in a setting of prevalence of 14% LFD positive results.
Table 3
Evaluations of the Innova LFD across Phases 24. The table dem-
onstrates the kit failure rate.
Innova LFD evaluation phase LFD failures (%)
Phase 2 negatives 0/72 (0.0%)
Phase 2 positive dilution series 0/60 (0.0%)
Phase 2 positive extended dilution series 0/155 (0.0%)
Phase 2 Swab comparison 0/187 (0.0%)
Phase 3a positives 13/191 (6.8%)
Phase 3a negatives 50/990 (5.1%)
Phase 3b FALCON (Dry swabs- field) 27/267 (10.1%)
Phase 3b FALCON (Dry swabs- lab) 9/212 (4.2%)
Phase 3b FALCON (VTM swabs) 9/157 (5.7%)
Phase 4 hospital staff 17/358 (4.7%)
Phase 4 armed forces 6/157 (3.8%)
Phase 4 PHE staff 19/212 (8.9%)
Phase 4 school 1 311/1855 (16.8%)
Phase 4 school 2 + 3 + 4 14/2132 (0.7%)























































































































































































































































































































































































































































































































































































































































































































4 T. Peto et al. / EClinicalMedicine 36 (2021) 100924transfer of the liquid within the device from the reservoir onto the
test strip.
3.5. Sensitivity of LFDs against viral load determined by qPCR (Phase 3)
To date, seven swab-based LFDs have passed Phase 3a evaluation,
namely: Innova SARS-CoV-2 Antigen Rapid Qualitative Test (Innova),
Zhejiang orient Gene Biotech Co. Coronavirus Ag Rapid Test Cassette
(Swab) (Orient Gene), Anhui Deepblue Medical Technology COVID-
19 (Sars-CoV-2) Antigen Test kit (Colloidal Gold) (Deepblue), Fortress
Diagnostics Coronavirus Ag Rapid Test (Fortress), Roche SD Biosensor
Standard Q COVID-19 Ag Test (SD Bio swab), Surescreen Diagnostics
SARS-CoV-2 Antigen Rapid Test Cassette (Nasopharyngeal swab
(Surescreen) and Abbott Panbio COVID-19 Ag Rapid Test Device
(Abbott) (Supplementary Table 1). Three LFDs did not pass 3a evalua-
tion and the remaining LFDs are currently undergoing evaluation.
Four LFDs (Deepblue, Innova, Orientgene, Abbott) have passed Phase
3b evaluation in which the LFDs were used according to the manufac-
turer’s instructions by either a laboratory worker and (for Innova) a
health care worker and the results were compared to the viral load of
a second swab a second swab taken at the same time and placed in
viral transport medium for subsequent qPCR. (Table 4). There was a
Fig. 1. A. Logistic curves showing association between viral detection/sensitivity and viral load (RNA copies/ml) for Abbott, Deepblue, Orientgene LFDs when performed by Lab
worker. B. Logistic curve showing association between viral antigen detection/sensitivity and viral load (RNA copies/mL and Ct) for Innova LFD when performed by trained labora-
tory scientists and trained healthcare workers.
T. Peto et al. / EClinicalMedicine 36 (2021) 100924 5strong association between viral load detection (RNA copies/mL)
determined through RT-PCR and viral antigen detection by LFD
(Fig. 1). Confirming earlier analyses, sensitivity of LFDs is highest in
samples with higher viral loads [18 19].
Optimal viral antigen detection/sensitivity when performed by
laboratory scientists, was 78.8% (95% CI 72.484.3%; 156/198 cases
where a paired PCR was performed; see below for differing perfor-
mance by test operator category). Subgroup analyses showed there
were no discernible differences in viral antigen detection/sensitivity
in those without symptoms vs. symptomatic individuals (27/41
[65.9%] vs. 249/344 [72.4%], p = 0.37). We did not find any evidence
of associations between LFD positivity and symptoms or past medical
history, with the exception of presence of headache (Supplementary
Table 2).Fig. 2. Effect of training and operator on the viral detection/sensitivity of the Innova LFD3.6. LFD test performance by operator
As part of Phase 3b-4 evaluations, work was performed to report
on the effect of the operator on viral antigen detection/sensitivity in
RT-PCR-positive cases using the Innova LFD. Tests were classified
according to whether they were performed by a laboratory scientist,
a fully trained research health care worker or by a self-trained lay
individual working at a regional NHS Test and Trace centre. Perfor-
mance was optimal when the LFD was used by laboratory scientists
(156/198 LFDs positive [78.8%, 95% CI: 72.484.3%]) relative to
trained healthcare-workers (156/223 LFDs positive [70.0%, 95% CI:
63.575.9%]) and self-trained members of the public given a protocol
(214/372 LFDs positive [57.5%, 95% CI: 52.362.6%]; p<0.0001)
(Fig. 2).in COVID-19 PCR-positive patients. Whiskers represent 95% confidence intervals.
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We report on our national evaluation of SARS-CoV-2 viral antigen-
detecting LFDs, focussing on the Innova SARS-CoV-2 Antigen Rapid
Qualitative Test, which has a viral antigen detection (sensitivity) of
78.8% when performed by laboratory scientists and a specificity of
99.7%, using RT-PCR as ‘gold standard’ for positive and negative sta-
tus. Test performance to detect SARS-CoV-2-positive samples was
improved at lower Ct values/higher viral loads, and were >90% at Ct
values <25 (equating to ~390 pfu/mL, 100,000 RNA copies/ml). We
are not able to comment on whether there is a concentration of viral
load where LFDs become more sensitive than PCR and further work
is required on the precise lower bound of detection using a greater
number of samples. However, there is an expanding body of evidence
that suggests viral load/antigen is important as individuals with the
highest viral loads are the most infectious, [20] and the presence/
absence of viral antigens determined by LFDs is more strongly associ-
ated with a viral culture than RT-PCR positivity [21]. In our evalua-
tion, test performance was largely maintained across different
settings and cohorts; however, performance was partly operator-
dependent and kit failures are not infrequent.
Our experience is that many LFDs entering our national evaluation
program do not perform at a level required for mass population
deployment and this reflects the literature. To date, an increasing
number of evaluations of SARS-CoV-2 antigen-detecting LFD have
been published with variable results. A number of LFDs show good,
[22,23,13,19,24,25] or acceptable sensitivity and specificity, [26,27]
however, many studies have identified tests with poor sensitivities
or specificities [28,15].
A challenge for most countries during the SARS-CoV-2 pandemic
has been the expansion of capacity for diagnostic testing to support
the identification of symptomatic and asymptomatic cases. This
would aid in offering testing to “contacts” of COVID-19 and enable
targeted testing to better safeguard vulnerable populations e.g. care
home residents. Reliance on RT-PCR involves significant infrastruc-
tural and specialist human resources to implement at increasing
scale. Both the World Health Organisation and European commission
have issued guidance supporting wider implementation of antigen-
targeting LFDs, and in November, Slovakia became the first country
in the world to implement entire population testing using LFDs
[1,3,29]. The UK has similar aspirations to pursue a strategy of mass
testing and has implemented a city wide mass testing in Liverpool
using the Innova LFD in this study [30].
It is important to note that there are some potential issues with
considering RT-PCR as the gold standard test for COVID-19. Many
individuals have persisting viral RNA fragments that can linger for
weeks-months without any evidence of active viral replication; in
this instance a PCR-positive is likely to overcall the “infectious” status
of an individual [31]. Indeed, when compared to the ability to per-
form viral culture, data suggest that RT-PCR tends to overestimate
the presence of replicating or infectious virions. [32].
In field testing, performance of the Innova LFD was dependent on
the test operator. Individuals who had read a protocol immediately
prior to self-sampling did not perform as well as individuals with
hands-on training, or clinical laboratory personnel who had per-
formed several hundred LFD tests. Optimal test performance, is
therefore likely to reflect the ability of operators to perform the test
according to the manufacturer’s instructions in the field. In a hospital
staff testing setting, recently published work confirmed good perfor-
mance of these tests for home-testing [33]. It is assumed that the use
of LFDs to successfully identify individuals with higher viral loads
and enabling an earlier diagnosis will be of benefit in interrupting
transmission. However, like any new test, the magnitude of benefit
versus potential for theoretical harm in different settings will need to
be ascertained and has caused ongoing debate in the academic com-
munity [34 35].SARS-CoV-2 control will benefit from a variety of testing strate-
gies. This might include those optimised for determining past infec-
tion/exposure (e.g. serology), those that are of benefit in determining
current/recent infection (e.g. RT-PCR), or those identifying potential
infectivity. A combination of approaches incorporating the strengths
of each of these tests can be effectively used for individuals and for
population-level management of the pandemic. Based on our analy-
ses we do believe there is a role for LFDs in clinical use using the 4
LFDs identified. We do not believe comparisons between these LFDs
is appropriate in this dataset as there are slight difference in both the
viral load bands and number of tests performed. Approaches to test-
ing will remain relevant even when effective vaccines become avail-
able as it may take several months for an appreciable effect on
transmission to be fully realised [36].
In conclusion, we completed late stage evaluations of seven LFDs.
We report sensitivities of 7080% and specificities 99.7% for each
LFD evaluated in phase 3b, which involved testing by laboratory per-
sonnel or trained healthcare professionals. To identify patients with
higher viral loads (Ct<25), each LFD had >90% sensitivity. Sensitivity
was lower in phase 4 evaluations, while specificity was maintained.
The simplicity of LFDs, without a requirement for specialist training
or equipment, mean that they are an attractive option for mass test-
ing. Future research should focus on post-implementation evaluation
of diagnostic accuracy and strategies to improve the sensitivity and
accuracy of these tests. This will include the potential benefits of reg-
ular serial sampling, digital results interpretation and incorporation
of enhanced training strategies utilising videos to improve accuracy
and reduce transmission.
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